Real World Efficacy of Naltrexone/Bupropion for Weight Management in Obesity and After Bariatric Surgery DOI Creative Commons
Roman Vangoitsenhoven,

Marie Yskout,

J. Hostè

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 29, 2024

Abstract Background Insufficient weight loss or regain after metabolic and bariatric surgery (MBS) is frequent, the evidence to support use of pharmacotherapy for management limited. Methods In this single-centre retrospective cohort study, effectiveness naltrexone/bupropion (NB) control in surgery-naive post-MBS patients was evaluated. Data collected between 2016 2022 on all consecutive started NB multidisciplinary consult. Patients received weekly dose escalation up 32/360 mg daily per manufacturer’s protocol, with submaximal doses administered cases adverse effects sufficient therapeutic response. Weight evolution, status, adherence events were analysed at 4 12 months initiation. are presented as median (interquartile range). Results A total 153 initiated therapy, including 111 who surgery-naive, 42 prior MBS. The time MBS 7.7 years (4.3, 15.3). Among patients, 18 (42.9%) had undergone Roux-en-Y gastric bypass 11 (26.2%) sleeve gastrectomy. At initiation NB, 46.8% 66.7% remained using a 6.4% (3.0, 10.1) 6.1% (2.4, 2.0) respectively. 12-months, 38.5% 60.7% continued 8.8% (5.0, 16.7) 11.1% (4.7, 19.8) There no statistically significant difference group. not significantly influenced by whether maximal reached both (p = 0.38) 0.61). Conclusion Real-world data show that treatment equally effective experiencing surgery, regardless administered.

Language: Английский

What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals? DOI Creative Commons
María Gómez‐Martín, Oliver J. Canfell, Li Kheng Chai

et al.

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: May 7, 2025

Language: Английский

Citations

0
Medicatie voor obesitas: vooruitgang en uitdagingen DOI Creative Commons
Marcel H.A. Muskiet, Mariëtte R. Boon

Nederlands Tijdschrift voor Diabetologie, Journal Year: 2024, Volume and Issue: 22(3), P. 5 - 14

Published: Aug. 27, 2024

Citations

1
A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease DOI Creative Commons
Waleed AlHabeeb, Abdulhalim Jamal Kinsara, Abeer Bakhsh

et al.

Journal of the Saudi Heart Association, Journal Year: 2024, Volume and Issue: 36(3), P. 263 - 300

Published: Oct. 17, 2024

Objectives: The obesity pandemic is a major public health concern in Saudi Arabia, with significant impact on cardiovascular disease (CVD). This position statement aims to provide an overview of available evidence as well the recommendations Heart Association management associated CVD.

Language: Английский

Citations

0
Real World Efficacy of Naltrexone/Bupropion for Weight Management in Obesity and After Bariatric Surgery DOI Creative Commons
Roman Vangoitsenhoven,

Marie Yskout,

J. Hostè

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 29, 2024

Abstract Background Insufficient weight loss or regain after metabolic and bariatric surgery (MBS) is frequent, the evidence to support use of pharmacotherapy for management limited. Methods In this single-centre retrospective cohort study, effectiveness naltrexone/bupropion (NB) control in surgery-naive post-MBS patients was evaluated. Data collected between 2016 2022 on all consecutive started NB multidisciplinary consult. Patients received weekly dose escalation up 32/360 mg daily per manufacturer’s protocol, with submaximal doses administered cases adverse effects sufficient therapeutic response. Weight evolution, status, adherence events were analysed at 4 12 months initiation. are presented as median (interquartile range). Results A total 153 initiated therapy, including 111 who surgery-naive, 42 prior MBS. The time MBS 7.7 years (4.3, 15.3). Among patients, 18 (42.9%) had undergone Roux-en-Y gastric bypass 11 (26.2%) sleeve gastrectomy. At initiation NB, 46.8% 66.7% remained using a 6.4% (3.0, 10.1) 6.1% (2.4, 2.0) respectively. 12-months, 38.5% 60.7% continued 8.8% (5.0, 16.7) 11.1% (4.7, 19.8) There no statistically significant difference group. not significantly influenced by whether maximal reached both (p = 0.38) 0.61). Conclusion Real-world data show that treatment equally effective experiencing surgery, regardless administered.

Language: Английский

Citations

0